Transforming life sciences innovation in Japan through the creation of venture-backed global companies.
Employees: 11-50
Portfolio 7
| Date | Name | Website | Total Raised | Location |
| 04.05.2022 | Protected:... | kirilys.com | - | - |
| 04.05.2022 | Pathalys P... | pathalys.com | $255M | United Sta... |
| 02.12.2021 | HilleVax | hillevax.com | $135M | United Sta... |
| 02.12.2021 | Aculys Pha... | aculys.com | $84M | Japan, Kan... |
| 17.04.2021 | Mineralys ... | mineralystx.com | $470M | Canada |
| - | Exalys The... | exalystx.com | - | - |
| - | Phathom Ph... | phathompharma.com | $140M | United Sta... |
News 38
| Date | Title | Description |
| 09.02.2023 | Mineralys Therapeutics Announces Pricing of Upsized Initial Public Offering | The offering is expected to close on February 14, 2023, subject to the satisfaction of customary closing conditions. In addition, Mineralys has granted the underwriters a 30-day option to purchase up to an additional 1,800,000 shares of com... |
| 24.01.2023 | Aculys Pharma Initiates a Phase 3 Trial of pitolisant Treating Patients with Excessive Daytime Sleepiness Associated with Obstructive Sleep Apnea Syndrome | This trial is a multi-center, randomized, double-blind, placebo-controlled, parallel-group study (Part 1) and a subsequent multi-center, open-label, long-term extension study (Part 2) to assess the safety and efficacy of pitolisant in the J... |
| 18.01.2023 | Pathalys Pharma Raises $150 Million in Secured Product Financing and Equity led by Abingworth; Forms Strategic Collaboration with Launch Therapeutics to Advance Upacicalcet through Pivotal Phase 3 Stu... | Research Triangle Park, North Carolina and Boston, Massachusetts, January 18, 2023 — Pathalys Pharma, Inc., a private, late-stage biopharma company co-founded by Catalys Pacific and DaVita Venture Group, and Launch Therapeutics (Launch Tx),... |
| 08.01.2023 | Phathom Pharmaceuticals Announces Positive Topline Results from Phase 3 PHALCON-NERD-301 Trial Evaluating Daily Dosing of Vonoprazan for Symptomatic Non-Erosive Gastroesophageal Reflux Disease (NERD) | FLORHAM PARK, N.J., Jan. 08, 2023 (GLOBE NEWSWIRE) — Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases and disorders, announced... |
| 10.11.2022 | Aculys Pharma initiates a phase 3 clinical study of a diazepam nasal spray: an antiepileptic drug for the treatment of epileptic seizures | This phase 3 study, conducted in Japan, is a multi-center, open-label study in children with status epilepticus and those at risk for status epilepticus to assess the efficacy and safety of NRL-1. Please visit the following site for detaile... |
| 08.11.2022 | Aculys Pharma initiates a phase 3 clinical study of the histamine H3 receptor antagonist/inverse agonist pitolisant in patients with narcolepsy in Japan | This phase 3 study consists of a multi-institutional double-blind, randomized, placebo-controlled, parallel group-comparison study (Part 1) and an open-label long-term treatment study (Part 2) to assess the efficacy and safety of pitolisant... |
| 03.05.2022 | HilleVax Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares | Registration statements relating to the offering have been filed with the Securities and Exchange Commission and became effective on April 28, 2022. A prospectus relating to and describing the terms of the offering has been filed with the S... |
| 03.05.2022 | Phathom Pharmaceuticals Announces FDA Approval of VOQUEZNA™ TRIPLE PAK™ (vonoprazan, amoxicillin, clarithromycin) and VOQUEZNA™ DUAL PAK™ (vonoprazan, amoxicillin) for the Treatment of H. pylori Infec... | FLORHAM PARK, N.J., May 03, 2022 (GLOBE NEWSWIRE) — Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, announced today the U.S.... |
| 02.05.2022 | HilleVax Announces Initiation of Phase 2b Clinical Trial of HIL-214 Vaccine Candidate for the Prevention of Norovirus-Related Acute Gastroenteritis in Infants | The clinical trial is a Phase 2b, randomized, double-blind, placebo-controlled study to evaluate the efficacy, safety, and immunogenicity of HIL-214 in infants of approximately 5 months of age at time of initial vaccination at sites in the ... |
| 30.03.2022 | Phathom Pharmaceuticals Submits Vonoprazan NDA to FDA for the Treatment of Erosive Esophagitis | Erosive esophagitis, a major type of gastroesophageal reflux disease (GERD), affects approximately 20 million people in the U.S. In addition to experiencing troubling heartburn symptoms, patients with inadequately treated EE may progress to... |
Show more
Mentions in press and media 5
| Date | Title | Description |
| 10.10.2025 | Renalys Announces Completion of Primary Endpoint Data Collection for Phase III Clinical Trial of Sparsentan for Iga Nephropathy in Japan | TOKYO, Oct. 10, 2025 /PRNewswire/ -- Renalys Pharma, Inc. (Headquarters: Chuo-ku, Tokyo; "Renalys") announced today that it has completed data collection for the primary endpoint in the Phase III clinical trial of sparsentan (deve... |
| 01.10.2025 | Crystalys Therapeutics: $205 Million Series A Raised For Transforming Gout Treatment | Crystalys Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing innovative therapies for gout, a condition characterized by high levels of uric acid in the blood that can lead to painful arthritis flare-ups. The... |
| 30.09.2025 | Crystalys Therapeutics Raises in $205M Series A Funding | Crystalys Therapeutics, a San Diego, CA-based clinical-stage biopharmaceutical company, raised $205M in Series A funding. The round was led by Novo Holdings, SR One and Catalys Pacific with participation from a broad syndicate of investors,... |
| 23.03.2022 | Catalys Pacific Launches Kirilys Therapeutics as a Multi-asset Precision Oncology Company | SAN FRANCISCO–(BUSINESS WIRE)–March 23, 2022– Kirilys Therapeutics, Inc., a private, preclinical-stage biopharmaceutical company founded by investment firm Catalys Pacific, announced today that the Company completed a seed financing led by ... |
| 17.06.2019 | Life Sciences Venture Capital Firm Catalys Pacific Launches in Japan | Catalys Pacific, a Japanese life sciences venture capital firm, has just launched its first fund. Led by BT Slingsby, Takeshi Takahashi, and Bill Watt, Catalys Pacific is an independent venture capital firm focusing on early-stage investmen... |